(For eligible participants, study-related treatments and tests are provided at no cost by the clinical trial sponsors.)
1. Prospective, Single-Center, Two-Arm Phase I Trial of Tumor Neoantigen Vaccine SarcVac + Tumor-Specific Lymphocyte Infusion for Advanced or Unresectable Solid Tumors (Sarcoma-Dominant) Refractory to Standard Therapy
● Indication: Advanced/unresectable solid tumors (sarcoma-dominant), refractory to standard therapy
● Contact: Assistant Peng, Tel: +86-18122111964
2. Multicenter, Prospective, Open-Label, Single-Arm Phase II Study of Gemcitabine + Oxaliplatin + Eribulin (GOE) for Relapsed/Refractory Advanced Male Germ Cell Tumors
● Indication: Relapsed or metastatic germ cell tumors
● Principal Investigator: An Xin / Shi Yanxia
● Contact: Assistant Peng, Tel: +86-18122111964
3. Randomized, Multicenter Phase II Study of Chidamide + Fulvestrant ± Sintilimab as Second-Line Treatment for HR-Positive, HER-2-Negative Breast Cancer
● Indication: HR-positive, HER-2-negative breast cancer
● Principal Investigator: Shi Yanxia
● Contact: Assistant Peng / Assistant Zuo, Tel: +86-18122111964
4. YY-20394-015: International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study of Linperlisib + CHOP vs. CHOP for Treatment-Naïve Peripheral T-Cell Lymphoma
● Indication: Treatment-naïve peripheral T-cell lymphoma
● Principal Investigator: Cai Qingqing
● Contact & Outpatient Info:
○ Dr. Cai Qingqing: Yuexiu Campus, Mon all day & Thu AM (Room 315)
○ Dr. Xia Yi: Yuexiu Campus, Tue AM & Thu PM (Room 313)
○ Research Nurse: Nurse Yang, Tel: +86-18826275445
5. Multicenter, Prospective, Open-Label, Single-Arm Phase II Study of Toripalimab + EP/EC as First-Line Treatment for Locally Advanced or Metastatic Small Cell Carcinoma of the Urinary System
● Indication: Small cell carcinoma of urinary system (kidney, ureter, bladder, urethra, prostate)
● Principal Investigator: Shi Yanxia
● Contact: Assistant Peng / Assistant Zuo, Tel: +86-18122111964
6. Phase II Study of Utidelone (UTD1) Injection for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
● Indication: Metastatic castration-resistant prostate cancer (mCRPC) refractory to standard therapy
● Principal Investigator: Shi Yanxia
● Contact: Assistant Peng / Assistant Zuo, Tel: +86-18122111964
7. Efficacy and Safety Exploratory Study of Sintilimab + Eribulin + Carboplatin for Anthracycline- and Taxane-Pretreated Advanced Triple-Negative Breast Cancer
● Indication: Advanced triple-negative breast cancer
● Principal Investigator: Shi Yanxia / An Xin
● Contact: Assistant Peng / Assistant Zuo, Tel: +86-18122111964
8. Multicenter, Open-Label Phase I Trial of TQB2252 Injection: Safety and Pharmacokinetics in Advanced Malignant Tumor Patients
● Indication: Solid tumors (advanced malignant tumors)
● Principal Investigator: Zhang Xing
● Contact: Research Nurses Cen Huafang / Yang Qiuyi, Tel: +86-14716938514 / +86-18826275445
Note:
Official recruitment details and QR codes are available on the SYSUCC Clinical Trial Directory.
Source Clarification: The clinical trials listed above are sourced from public announcements by Sun Yat-sen University Cancer Center. United Life Science provides this information as a public directory service for oncology research and patient empowerment.
For more recruitment information, visit: https://www.sysucc.org.cn/node/9079
WhatsApp
Address
Mailing Form
Languages
English
WhatsApp